

Clinical Policy: Finerenone (Kerendia)

Reference Number: ERX.NPA.160

Effective Date: 12.01.21

Last Review Date: 11.21

Line of Business: Commercial, Medicaid

[Revision Log](#)

See **Important Reminder** at the end of this policy for important regulatory and legal information.

Description

Finerenone (Kerendia®) is a non-steroidal mineralocorticoid receptor antagonist.

FDA Approved Indication(s)

Kerendia is indicated to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.

It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Kerendia is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Chronic Kidney Disease (must meet all):

1. Diagnosis of both of the following (a and b):
 - a. CKD;
 - b. T2D;
2. Age \geq 18 years;
3. Both of the following (a and b):
 - a. eGFR between 25 and 75 mL/min/1.73 m²;
 - b. Urine albumin creatinine ratio (UACR) \geq 30 mg/g;
4. Member is currently receiving an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) at maximally tolerated doses for \geq 4 weeks, unless clinically significant adverse effects are experienced or all are contraindicated;
5. Dose does not exceed 20 mg (1 tablet) per day.

Approval duration: 12 months

B. Other diagnoses/indications

1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy

A. Chronic Kidney Disease (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed 20 mg (1 tablet) per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

- Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.
Approval duration: Duration of request or 12 months (whichever is less); or
- Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

ACE: angiotensin converting enzyme
ARB: angiotensin receptor blocker
CKD: chronic kidney disease
eGFR: estimated glomerular filtration rate

FDA: Food and Drug Administration
T2D: type 2 diabetes
UACR: urine albumin creatinine ratio

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
ACEIs		
captopril (Capoten®)	Doses vary	450 mg/day
enalapril (Vasotec®, Epaned®)		40 mg/day
fosinopril (Monopril®)		80 mg/day
lisinopril (Prinivil®, Zestril®, Qbrelis®)		80 mg/day
perindopril (Aceon®)		16 mg/day
quinapril (Accupril®)		80 mg/day
ramipril (Altace®)		20 mg/day
trandolapril (Mavik®)		8 mg/day
ARBs		
candesartan (Atacand®)	Doses vary	32 mg/day
losartan (Cozaar®)		100 mg/day
telmisartan (Micardis®)		80 mg/day
valsartan (Diovan®)		320 mg/day

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): concomitant use with strong CYP3A4 inhibitors, adrenal insufficiency
- Boxed warning(s): none

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
CKD associated with T2D	10 mg or 20 mg PO QD based on eGFR and serum potassium thresholds. Increase to target dose of 20 mg PO QD after 4 weeks based on eGFR and serum potassium thresholds.	20 mg/day

VI. Product Availability

Tablets: 10 mg, 20 mg

VII. References

1. Kerendia Prescribing Information. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; July 2021. Available at: <https://www.kerendia-us.com/>. Accessed July 29, 2021.
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney inter., Suppl.* 2013; 3: 1–150.
3. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med.* 2020 Dec;383(23):2219-2229.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created	08.17.21	11.21

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2021 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.